A Phase I Study of Temozolomide, Oral Irinotecan, and Vincristine for Children With Refractory Solid Tumors.
Latest Information Update: 18 Sep 2021
Price :
$35 *
At a glance
- Drugs Irinotecan; Temozolomide; Vincristine
- Indications Solid tumours
- Focus Adverse reactions; Pharmacogenomic
- 20 Feb 2014 Biomarkers information updated
- 21 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Jul 2008 Status changed from recruiting to in progress, as reported by ClinicalTrials.gov.